Synthetic educational example. Do not self-treat: a qualified treating physician must verify the sources, patient data, contraindications, and final plan.
Patient
BMA-MLH1_GERMLINE_PROSTATE · Algorithm: ALGO-PROSTATE-MCRPC-1L
Clinical significance of mutations (ESCAT)
Tumor-board context — the engine does not use these tiers to rank tracks
| Biomarker | Variant | ESCAT | Evidence | Clinical significance | Drugs | Sources |
|---|
| No clinically actionable variants matched in this profile. |
| Biomarker | Status |
|---|
| BIO-DMMR-IHC | BIO definition in KB; no ESCAT BMA entry — verify with clinician |
Primary current-line option
- Indication
- IND-PROSTATE-MCRPC-1L-ARPI
- Regimen
- ADT + enzalutamide (continuous)
- Drugs + NSZU
- Leuprolide (DRUG-LEUPROLIDE) 11.25 mg IM q3 months · Continuous · IM ✓ NSZU covered
- Enzalutamide (DRUG-ENZALUTAMIDE) 160 mg PO daily · Continuous · PO ✓ NSZU covered
- Supportive care
- SUP-BONE-HEALTH-PROSTATE
- Reason
- Primary current-line option selected by ALGO-PROSTATE-MCRPC-1L at step 4.
Other current-line alternatives (2 tracks)
Same treatment line; review when biomarker, access, contraindication, or patient-context assumptions change.
- Indication
- IND-PROSTATE-MCRPC-1L-PARPI
- Regimen
- Olaparib monotherapy (mCRPC, HRR-mutant)
- Drugs + NSZU
- Olaparib (DRUG-OLAPARIB) 300 mg PO BID continuous · Until progression or unacceptable toxicity · PO ⚠ NSZU — not for this indication
- Supportive care
- SUP-BONE-HEALTH-PROSTATE
- Reason
- Current-line alternative presented for HCP consideration
- Indication
- IND-PROSTATE-MCRPC-2L-LU-PSMA
- Regimen
- Lutetium-177 PSMA-617 radioligand therapy
- Drugs + NSZU
- Lutetium-177 PSMA-617 (DRUG-LUTETIUM-177-PSMA) 7.4 GBq IV · q6 weeks × 6 cycles · IV ✗ Not registered in UA
- Supportive care
- SUP-BONE-HEALTH-PROSTATE
- Reason
- Current-line alternative presented for HCP consideration
Pre-treatment investigations
Investigations before treatment start · critical / standard / desired · merged across tracks
| ID | Name | Priority | Category | Where to order | Needed for |
|---|
| TEST-CBC | Complete Blood Count with Differential | Critical | lab | — | standard |
| TEST-CMP | Comprehensive Metabolic Panel | Critical | lab | — | standard |
| TEST-PSA-SERUM | Serum PSA | Critical | — | — | all tracks |
| TEST-BONE-SCAN | Whole-body Tc-99m MDP bone scintigraphy | Standard | — | — | all tracks |
| TEST-GERMLINE-BRCA-PANEL | Germline BRCA1/2 + HRR panel sequencing | Standard | — | CSD Lab: M089 | all tracks |
| TEST-PSMA-PET | PSMA-PET/CT (Ga-68 or F-18) | Standard | — | — | standard |
| TEST-SOMATIC-HRR-PANEL | Tumor-tissue (or ctDNA) HRR-pathway NGS panel | Standard | — | CSD Lab: M065
CSD Lab ✓ (code TBC) | aggressive |
| TEST-TESTOSTERONE-SERUM | Serum total testosterone | Standard | — | — | all tracks |
Red flags — PRO / CONTRA aggressive
PRO-AGGRESSIVE
Triggers that push toward the aggressive track
- AR (androgen receptor) gene amplification detected on tumor or ctDNA NGS in mCRPC — INFORMATIONAL signal of mechanistic ARSI resistance. AR amplification is one of the most common acquired resistance mechanisms to abiraterone / enzalutamide / apalutamide / darolutamide; detected in ~30-50% of post-ARSI mCRPC ctDNA samples. AR-amp argues against ARSI-after-ARSI sequencing (limited cross-class benefit) and for early switch to taxane chemotherapy (docetaxel, cabazitaxel) or radioligand 177Lu-PSMA-617 (if PSMA-PET-positive). FDA has NOT approved any therapy decision keyed on AR-amp status — surfaces in MDT brief to flag patients in whom further ARSI escalation is unlikely to add benefit. Companion to RF-PROSTATE-AR-V7-ARSI-RESISTANCE (AR-V7 splice variant); both detect distinct facets of AR-driven resistance.
References BIO-AR-AMPLIFICATION. Detection: ctDNA NGS (Guardant360, FoundationOne Liquid CDx) is the practical platform — tumor biopsy in mCRPC frequently fails (bone-only disease, low cellularity). Co-occurring resistance markers include…
RF-PROSTATE-AR-AMP-ARSI-RESISTANCESRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024SRC-EAU-PROSTATE-2024 - AR-V7 (androgen receptor splice variant 7) detected in CTCs / ctDNA in mCRPC — predictive marker of ARSI (abiraterone, enzalutamide, apalutamide, darolutamide) failure. PROPHECY (Antonarakis 2019): AR-V7-positive on Epic CTC IHC associated with HR ~3 for inferior PFS/OS on ARSI vs AR-V7-negative; switch to taxane (docetaxel, cabazitaxel) recovers responses. INFORMATIONAL — FDA has NOT approved any therapy decision keyed on AR-V7; surfaces in MDT brief to flag patients in whom ARSI-after-ARSI is unlikely to work.
Detection: Epic AR-V7 Nucleus Detect (CTC-IHC) is the most-validated platform; requires ≥5 CTC per 7.5 mL blood for an interpretable result (lower CTC counts are non-informative, not negative). Alternatives: PCR-based AR-V7 mRNA on CTCs…
RF-PROSTATE-AR-V7-ARSI-RESISTANCESRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024 - Metastatic prostate cancer with malignant epidural spinal cord compression (MESCC): new motor deficit, sensory level, cauda equina syndrome, severe back pain with vertebral metastasis — prostate is the most common solid tumor cause of MESCC
Per NCCN-PROSTATE supportive-care + EAU-PROSTATE 2024: dexamethasone 10 mg IV bolus + 4 mg q6h, MRI whole spine within 24 h, multidisciplinary surgical/RT review. Patchell criteria for surgery (single-level, ≥48 h expected survival…
RF-PROSTATE-CORD-COMPRESSIONSRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024SRC-EAU-PROSTATE-2024 - Germline or somatic BRCA1/2 mutation OR broader HRR pathway alteration (ATM, CDK12, PALB2, etc.) — predicts PARPi response; opens olaparib/talazoparib indication in mCRPC.
PROfound (olaparib) + TALAPRO-2 (talazoparib + enzalutamide) + MAGNITUDE (niraparib + abiraterone) define PARPi indications. BRCA1/2 largest benefit; broader HRR cohort smaller but positive. Germline + somatic testing recommended for ALL…
RF-PROSTATE-HIGH-RISK-BIOLOGYSRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024 - Pre-treatment HBV/HCV/HIV serology + dental evaluation (denosumab/zoledronate ONJ risk; lutetium-PSMA xerostomia) standard for mCRPC initiation.
Cross-disease HBV reactivation handled by RF-UNIVERSAL-HBV-REACTIVATION- RISK. Dental clearance pre-bone-modifying-agent unique to bone-meta diseases (prostate, breast, MM).
RF-PROSTATE-INFECTION-SCREENINGSRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024 - Renal dysfunction (CrCl <50 mL/min) or severe hepatic impairment (Child-Pugh C) — limits PARPi (olaparib renal-cleared) and ARPI (abiraterone hepatic) dosing.
Olaparib requires CrCl ≥31 (with dose-mod) for safe use; <30 avoid. Abiraterone Child-Pugh C: avoid. Surfaces in MDT as need for renal/ hepatic input.
RF-PROSTATE-ORGAN-DYSFUNCTIONSRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024 - PCWG3-defined PSA progression on systemic prostate-cancer therapy: ≥25% rise from nadir + ≥2 ng/mL absolute increase, confirmed by a second value ≥3 weeks later. Triggers re-imaging + MDT consideration of next-line therapy switch — but NOT alone sufficient to change line if radiographic + clinical disease stable (per PCWG3 + STAR criteria).
PSA-only progression on ARPI / chemotherapy is common (~30-40% of patients show PSA flare or transient rise). PCWG3 explicitly cautions against line switch on PSA alone — radiographic progression (RECIST 1.1 for soft tissue, PCWG3…
RF-PROSTATE-PSA-PROGRESSIONSRC-NCCN-PROSTATE-2025SRC-EAU-PROSTATE-2024 - Spinal cord compression OR rapid PSA doubling time (<3 months) OR new visceral metastases — emergency or aggressive-progression flag requiring urgent intervention or treatment intensification.
Spinal cord compression: emergent neurosurgical / RT consult AND immediate testosterone suppression (degarelix preferred for speed vs LHRH agonists). PSA doubling time <3 months in nmCRPC: criterion for ARPI initiation per NCCN. Visceral…
RF-PROSTATE-TRANSFORMATION-PROGRESSIONSRC-NCCN-PROSTATE-2025SRC-ESMO-PROSTATE-2024
CONTRA-AGGRESSIVE
Hard contraindications to escalation
What NOT to do
Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity
Standard plan (IND-PROSTATE-MCRPC-2L-LU-PSMA)
- НІКОЛИ не призначати без PSMA-ПЕТ/КТ-підтвердження — тільки PSMA-позитивна хвороба
- Не призначати при будь-якому PSMA-негативному осередку метастазування
- Не ігнорувати ниркову функцію — лютецій виводиться нирками; ГФК <30 = протипоказання
- Не пропускати тестування HRR/BRCA до призначення — PARPi перевершує при BRCA1/2
- Не призначати без підтримки ядерно-медичного відділу з радіотерапевтичною ліцензією
Timeline
Treatment timeline — derived from regimen + monitoring schedule
Standard plan
Induction · ADT + enzalutamide (continuous)
28-day cycles × Continuous until progression or unacceptable toxicity
Aggressive plan
Induction · Olaparib monotherapy (mCRPC, HRR-mutant)
28-day cycles × Continuous until progression
Standard plan
Induction · Lutetium-177 PSMA-617 radioligand therapy
42-day cycles × 6 (extend to 8 if responding and tolerated, per protocol)
MDT brief
Discussion questions (5, 2 blocking)
OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist
BLOCKING OQ-BIOMARKER-GLEASON-ISUP
What is the status of Gleason score / ISUP grade group (BIO-GLEASON-ISUP)? It is required by track(s): IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: Gleason / ISUP grade group (1-5) — mandatory pathologic stratifier across all prostate cancer indications.
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ medical_oncologist
BLOCKING OQ-BIOMARKER-PSA
What is the status of Prostate-specific antigen (PSA) (BIO-PSA)? It is required by track(s): IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: PSA baseline + on-treatment per PCWG3 — mandatory response/progression marker; reportable across all systemic prostate indications.
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ medical_oncologist
OQ-BIOMARKER-HRR-PANEL
What is the status of Homologous recombination repair (HRR) gene panel status (BIO-HRR-PANEL)? It is required by track(s): IND-PROSTATE-MCRPC-1L-PARPI. Expected value: positive.
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ molecular_geneticist
OQ-BIOMARKER-PSMA-PET
What is the status of PSMA-PET imaging avidity (BIO-PSMA-PET)? It is required by track(s): IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: PSMA-PET/CT POSITIVE — MANDATORY (68Ga-PSMA-11 or 18F-DCFPyL preferred).
A treatment-track biomarker requirement is missing from the patient profile; the MDT should verify the test result, method, specimen, and date before relying on this option.
→ medical_oncologist
MDT talk tree (6 steps)
| # | Owner | Topic | Action |
|---|
| 1 | medical_oncologist | Biomarker status BLOCKING | What is the status of Gleason score / ISUP grade group (BIO-GLEASON-ISUP)? It is required by track(s): IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: Gleason / ISUP grade group (1-5) — mandatory pathologic stratifier across all prostate cancer indications. |
| 2 | medical_oncologist | Biomarker status BLOCKING | What is the status of Prostate-specific antigen (PSA) (BIO-PSA)? It is required by track(s): IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: PSA baseline + on-treatment per PCWG3 — mandatory response/progression marker; reportable across all systemic prostate indications. |
| 3 | hematologist | Staging / disease burden | What is the current LDH? Marker of tumor burden and transformation. |
| 4 | medical_oncologist | Biomarker status | What is the status of PSMA-PET imaging avidity (BIO-PSMA-PET)? It is required by track(s): IND-PROSTATE-MCRPC-2L-LU-PSMA. Expected value: PSMA-PET/CT POSITIVE — MANDATORY (68Ga-PSMA-11 or 18F-DCFPyL preferred). |
| 5 | molecular_geneticist | Biomarker status | What is the status of Homologous recombination repair (HRR) gene panel status (BIO-HRR-PANEL)? It is required by track(s): IND-PROSTATE-MCRPC-1L-PARPI. Expected value: positive. |
| 6 | clinical_pharmacist | Specialist review | Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication. |
Skills (recommended) — for consideration (2)
- Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.
- Molecular geneticist / molecular oncologist recommended
Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.
Owns: OQ-BIOMARKER-HRR-PANEL
Data quality
Incomplete for default-track review. Default-track review is incomplete until required biomarker gaps are resolved.
- Biomarker coverage: 0/4 known (0%), 4 missing, 2 default-track gaps
- Unevaluated RedFlags: RF-ATM-CONFIRMED-CARRIER, RF-ATM-FAMILY-HISTORY-SUSPICION, RF-BRCA-CONFIRMED-CARRIER, RF-BRCA-HBOC-FAMILY-HISTORY-SUSPICION, RF-CASCADE-BRCA-FDR-POSITIVE, RF-CASCADE-FAP-FDR-POSITIVE, RF-CASCADE-LYNCH-FDR-POSITIVE, RF-CHAARTED-HIGH-VOLUME-MHSPC, RF-CHEK2-CONFIRMED-CARRIER, RF-CHEK2-FAMILY-HISTORY-SUSPICION, RF-FAP-FAMILY-HISTORY-SUSPICION, RF-LATITUDE-HIGH-RISK-MHSPC, RF-LYNCH-CONFIRMED-CARRIER, RF-LYNCH-FAMILY-HISTORY-SUSPICION, RF-PAN-ATM-CHEK2-CDK12-PARPI-CANDIDATE, RF-PAN-BRCA-SOMATIC-PARPI-CANDIDATE, RF-PAN-PALB2-PARPI-CANDIDATE, RF-PROSTATE-AR-AMP-ARSI-RESISTANCE, RF-PROSTATE-AR-V7-ARSI-RESISTANCE, RF-PROSTATE-CORD-COMPRESSION, RF-PROSTATE-FRAILTY-AGE, RF-PROSTATE-HIGH-RISK-BIOLOGY, RF-PROSTATE-INFECTION-SCREENING, RF-PROSTATE-ORGAN-DYSFUNCTION, RF-PROSTATE-PSA-PROGRESSION, RF-PROSTATE-TMPRSS2-ERG-PROGNOSTIC, RF-PROSTATE-TRANSFORMATION-PROGRESSION
| Missing biomarker | Label | MDT owner | Default track | Required by | Next action |
|---|
BIO-GLEASON-ISUP | Gleason score / ISUP grade group | medical_oncologist | yes | IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA | Verify result, method, specimen, and report date before sign-off. Expected/constraint: Gleason / ISUP grade group (1-5) — mandatory pathologic stratifier across all prostate cancer indications |
BIO-PSA | Prostate-specific antigen (PSA) | medical_oncologist | yes | IND-PROSTATE-MCRPC-1L-ARPI, IND-PROSTATE-MCRPC-1L-PARPI, IND-PROSTATE-MCRPC-2L-LU-PSMA | Verify result, method, specimen, and report date before sign-off. Expected/constraint: PSA baseline + on-treatment per PCWG3 — mandatory response/progression marker; reportable across all systemic prostate indications |
BIO-HRR-PANEL | Homologous recombination repair (HRR) gene panel status | molecular_geneticist | no | IND-PROSTATE-MCRPC-1L-PARPI | Verify result, method, specimen, and report date before sign-off. Expected/constraint: positive |
BIO-PSMA-PET | PSMA-PET imaging avidity | medical_oncologist | no | IND-PROSTATE-MCRPC-2L-LU-PSMA | Verify result, method, specimen, and report date before sign-off. Expected/constraint: PSMA-PET/CT POSITIVE — MANDATORY (68Ga-PSMA-11 or 18F-DCFPyL preferred) |
Technical MDT skill metadata (2/16 activated in this plan)
All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).
| Specialist | skill_id | Version | Last reviewed | Sign-offs | Domain |
|---|
| Cellular therapy specialist (CAR-T) | cellular_therapy_specialist | v0.1.0 | 2026-04-25 | 0 | cellular_therapy |
| Clinical pharmacist | clinical_pharmacist | v0.1.0 | 2026-04-25 | 0 | clinical_pharmacy |
| Hematologist / oncohematologist | hematologist | v0.1.0 | 2026-04-25 | 0 | hematology_oncology |
| Hematopathologist (lymphoma / leukemia / myeloma) | hematopathologist | v0.1.0 | 2026-04-25 | 0 | hematopathology |
| Infectious disease / hepatology | infectious_disease_hepatology | v0.1.0 | 2026-04-25 | 0 | infectious_diseases |
| Medical oncologist (solid-tumor chemotherapist) | medical_oncologist | v0.1.0 | 2026-04-25 | 0 | solid_oncology |
| Molecular geneticist / molecular oncologist | molecular_geneticist | v0.1.0 | 2026-04-25 | 0 | molecular_oncology |
| Palliative care | palliative_care | v0.1.0 | 2026-04-25 | 0 | palliative_care |
| Pathologist (general) | pathologist | v0.1.0 | 2026-04-25 | 0 | pathology |
| Primary care / family physician | primary_care | v0.1.0 | 2026-04-25 | 0 | primary_care |
| Psycho-oncologist | psychologist | v0.1.0 | 2026-04-25 | 0 | psychosocial |
| Radiation oncologist | radiation_oncologist | v0.1.0 | 2026-04-25 | 0 | radiation_oncology |
| Radiologist | radiologist | v0.1.0 | 2026-04-25 | 0 | diagnostic_imaging |
| Social worker / case manager | social_worker_case_manager | v0.1.0 | 2026-04-25 | 0 | psychosocial |
| Surgical oncologist | surgical_oncologist | v0.1.0 | 2026-04-25 | 0 | surgical_oncology |
| Transplant specialist (BMT) | transplant_specialist | v0.1.0 | 2026-04-25 | 0 | cellular_therapy |
Sources cited
- SRC-ESMO-PROSTATE-2024: ESMO Clinical Practice Guideline on Prostate Cancer (2024)
- SRC-NCCN-PROSTATE-2025: NCCN Clinical Practice Guidelines — Prostate Cancer (2025.v3)
- SRC-VISION-PSMA-SARTOR-2021: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (2021)
Experimental options (clinical trials)
Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-08-17.
| NCT | Title | Phase | Status | Sponsor | UA | Signals | Eligibility (excerpt) |
|---|
| NCT07042256 | Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer | NA | RECRUITING | — | Small N (<50) Single country | |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | PHASE1 / PHASE2 | RECRUITING | — | Small N (<50) Surrogate endpoint only Single country | |
| NCT06067269 | Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | PHASE2 | RECRUITING | — | Single country | |
| NCT06369610 | Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer | PHASE2 | RECRUITING | — | Single country | |
| NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer | PHASE1 / PHASE2 | RECRUITING | — | Surrogate endpoint only | |
| NCT05022914 | PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE | N/A | RECRUITING | — | Surrogate endpoint only Single country | |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | PHASE1 | RECRUITING | — | Phase 1 only Small N (<50) Single country | |
| NCT06798558 | Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | PHASE2 | RECRUITING | — | Single country | |
| NCT05109208 | The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction | NA | RECRUITING | — | Small N (<50) Single country | |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | PHASE2 | RECRUITING | — | Surrogate endpoint only Single country | |
Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.
Option availability in Ukraine
Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).
| Option | UA registration | NSZU | Cost orientation | Access pathway |
|---|
| Standard plan ADT + enzalutamide (continuous) (REG-ADT-ENZALUTAMIDE) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Aggressive plan Olaparib monotherapy (mCRPC, HRR-mutant) (REG-OLAPARIB-MONO) | ✓ registered | ✓ covered | ₴-? — verify pathway | NSZU formulary |
| Standard plan Lutetium-177 PSMA-617 radioligand therapy (REG-LUTETIUM-PSMA) 1/1 component drug(s) not registered in Ukraine +1 | ✗ not registered | ✗ out-of-pocket | ₴-? — verify pathway | not recorded |
| Trial · NCT07042256 Feasibility of MR-Informed Adaptive Marker-less SBRT in Patients With Bilateral Hip Prostheses Undergoing SBRT for Localized Prostate Cancer No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT05000294 Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06067269 Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06369610 Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT07192614 A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT05022914 PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT07517198 Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06798558 Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT05109208 The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
| Trial · NCT06683846 Ivonescimab in the Treatment of Multiple Advanced Tumors No UA site listed — international referral required | — unknown | — unknown | self-pay: ₴0/course | Trial sponsor |
Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-08-17.